Conference Coverage: EHA 2023 – Focus on Leukemia and Myelodysplastic Syndrome (MDS) (Global)
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia
June 19, 2023
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Tapan M. Kadia, MD
MD Anderson Cancer Center, Houston, TX, USA
Ibrahim T. Aldoss, MD
City of Hope, Duarte, CA, USA
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL, USA
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Josep-Maria Ribera, MD, PhD
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Gert Ossenkoppele, MD, PhD
VU University Medical Center, Amsterdam, the Netherlands
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- New Developments in First-line Treatment of MDS
- New Developments in Targeted Treatment of MDS and Treatment of Relapsed/Refractory (R/R) MDS
- Advances in Acute Myeloid Leukemia (AML): Newly Diagnosed
- Advances in AML: Newly Diagnosed Elderly and/or Unfit and R/R Disease
- Advances in Acute Lymphoblastic Leukemia (ALL): Newly Diagnosed
- Advances in ALL: R/R Disease
